Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The platelet activation pathway is a complex network of signaling events triggered by various agonists including thrombin, ADP, thromboxane A2, collagen, and von Willebrand factor. These agonists bind to specific receptors on platelets, initiating intracellular signaling cascades that converge on common effectors like phospholipase C, leading to calcium mobilization, granule secretion, and integrin activation. This ultimately results in platelet shape change, adhesion, aggregation, and thrombus formation. The pathway involves multiple receptor families, G-proteins, kinases, and second messengers, making it a sophisticated system with built-in amplification and synergy between different activation mechanisms. Due to its central role in thrombosis, the platelet activation pathway contains numerous therapeutic targets for the prevention and treatment of cardiovascular diseases.
P2Y12 inhibitors block ADP-mediated platelet activation and aggregation. Glycoprotein IIb/IIIa inhibitors prevent fibrinogen binding and platelet aggregation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet activation signaling pathway.